Celastrol Prevents Atherosclerosis via Inhibiting LOX-1 and Oxidative Stress

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Gu, Lei ^a   Bai, Wenli ^a   Li, Sha ^a   Zhang, Yuqing ^b   Han, Yi ^c   Gu, Yue ^a   Meng, Guoliang ^a   Xie, Liping ^a   Wang, Jing ^a   Xiao, Yujiao ^a   Shan, Liyang ^a   Zhou, Suming ^b   Wei, Lei ^c   Ferro, Albert ^d   Ji, Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED JIANGNING HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELASTROL; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME DEGRADATION; IN VIVO STUDY; LIPID ANALYSIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; GENE EXPRESSION; MACROPHAGES; MICE; NF-KAPPA B; OXIDATIVE STRESS; REAL-TIME POLYMERASE CHAIN REACTION; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION; TRITERPENES;

MUS; TRIPTERYGIUM WILFORDII;

EID: 84879184415     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065477     Document Type: Article

References (55)

1. Scott J, (2007) The liver X receptor and atherosclerosis. N Engl J Med 357: 2195-2197.
2. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, et al. (1997) An endothelial receptor for oxidized low-density lipoprotein. Nature 386: 73-77.
3. Aoyama T, Chen M, Fujiwara H, Masaki T, Sawamura T, (2000) LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett 467: 217-220.
4. Li L, Sawamura T, Renier G, (2004) Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res 94: 892-901.
5. Fortuno A, San Jose G, Moreno MU, Diez J, Zalba G, (2005) Oxidative stress and vascular remodelling. Exp Physiol 90: 457-462.
6. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, et al. (2000) Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 275: 12633-12638.
7. Xu X, Gao X, Potter BJ, Cao JM, Zhang C, (2007) Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. Arterioscler Thromb Vasc Biol 27: 871-877.
8. Schmitz G, Grandl M, (2007) Role of redox regulation and lipid rafts in macrophages during Ox-LDL-mediated foam cell formation. Antioxid Redox Signal 9: 1499-1518.
9. Poli G, Leonarduzzi G, Biasi F, Chiarpotto E, (2004) Oxidative stress and cell signalling. Curr Med Chem 11: 1163-1182.
10. Jung HW, Chung YS, Kim YS, Park YK, (2007) Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med 39: 715-721.
11. Kim DH, Shin EK, Kim YH, Lee BW, Jun JG, et al. (2009) Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. Eur J Clin Invest 39: 819-827.
12. Jang SY, Jang SW, Ko J, (2011) Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor alpha. Cancer Lett 300: 57-65.
13. Yu X, Tao W, Jiang F, Li C, Lin J, et al. (2010) Celastrol attenuates hypertension-induced inflammation and oxidative stress in vascular smooth muscle cells via induction of heme oxygenase-1. Am J Hypertens 23: 895-903.
14. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, et al. (2006) Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 72: 1311-1321.
15. Hayden MS, Ghosh S, (2004) Signaling to NF-kappaB. Genes Dev 18: 2195-2224.
16. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, et al. (2000) Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 20: 645-651.
17. Gamble W, Vaughan M, Kruth HS, Avigan J, (1978) Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res 19: 1068-1070.
18. Sukhanov S, Higashi Y, Shai SY, Itabe H, Ono K, et al. (2006) Novel effect of oxidized low-density lipoprotein: cellular ATP depletion via downregulation of glyceraldehyde-3-phosphate dehydrogenase. Circ Res 99: 191-200.
19. Griffith OW, (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106: 207-212.
20. Yang H, Chen D, Cui QC, Yuan X, Dou QP, (2006) Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765.
21. Huang Y, Zhou Y, Fan Y, Zhou D, (2008) Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 264: 101-106.
22. Cheng J, Tian Z, Li JP, Hu HY, (2011) Celastrol attenuates atherosclerosis in Apolipoprotein E (apoE) knockout mice fed an atherogenic diet. Academic Journals 5 (9):: 1247-1251.
23. Wang Y, Zhao X, Jin H, Wei H, Li W, et al. (2009) Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 29: 173-179.
24. Itabe H, (2003) Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Pharm Bull 26: 1-9.
25. Musiek ES, Gao L, Milne GL, Han W, Everhart MB, et al. (2005) Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages. J Biol Chem 280: 35562-35570.
26. Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS, (1988) Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 27: 8706-8711.
27. Nathan C, Xie QW, (1994) Nitric oxide synthases: roles, tolls, and controls. Cell 78: 915-918.
28. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, et al. (1993) Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci U S A 90: 9730-9734.
29. Baldwin AS Jr, (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683.
30. Barnes PJ, Karin M, (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071.
31. Makarov SS, (2001) NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 3: 200-206.
32. Dhar A, Brindley JM, Stark C, Citro ML, Keefer LK, et al. (2003) Nitric oxide does not mediate but inhibits transformation and tumor phenotype. Mol Cancer Ther 2: 1285-1293.
33. Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, et al. (2004) Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279: 56053-56060.
34. Sassa H, Takaishi Y, Terada H, (1990) The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria. Biochem Biophys Res Commun 172: 890-897.
35. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, et al. (1999) Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 99: 3110-3117.
36. Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, et al. (2007) Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 100: 1634-1642.
37. Li DY, Chen HJ, Mehta JL, (2001) Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 52: 130-135.
38. Hofnagel O, Luechtenborg B, Eschert H, Weissen-Plenz G, Severs NJ, et al. (2006) Pravastatin inhibits expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins. Arterioscler Thromb Vasc Biol 26: 604-610.
39. Stein S, Lohmann C, Schafer N, Hofmann J, Rohrer L, et al. (2010) SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 31: 2301-2309.
40. Ishiyama J, Taguchi R, Yamamoto A, Murakami K, (2010) Palmitic acid enhances lectin-like oxidized LDL receptor (LOX-1) expression and promotes uptake of oxidized LDL in macrophage cells. Atherosclerosis 209: 118-124.
41. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, et al. (1996) Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781-786.
42. Ohara Y, Peterson TE, Harrison DG, (1993) Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546-2551.
43. Taye A, Saad AH, Kumar AH, Morawietz H, (2010) Effect of apocynin on NADPH oxidase-mediated oxidative stress-LOX-1-eNOS pathway in human endothelial cells exposed to high glucose. Eur J Pharmacol 627: 42-48.
44. Sies H, (1989) [Biochemistry of thiol groups: the role of glutathione]. Naturwissenschaften 76: 57-64.
45. Di Mascio P, Murphy ME, Sies H, (1991) Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols. Am J Clin Nutr 53: 194S-200S.
46. Gutteridge JM, Halliwell B, (2000) Free radicals and antioxidants in the year 2000. A historical look to the future. Ann N Y Acad Sci 899: 136-147.
47. Wang Y, Wang X, Sun M, Zhang Z, Cao H, et al. (2011) NF-kB activity-dependent P-selectin involved in ox-LDL-induced foam cell formation in U937 cell. Biochem Biophys Res Commun 411: 543-548.
48. Feng X, Zhang Y, Xu R, Xie X, Tao L, et al. (2010) Lipopolysaccharide up-regulates the expression of Fcalpha/mu receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody complex to activated human macrophages. Atherosclerosis 208: 396-405.
49. Lenardo MJ, Baltimore D, (1989) NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 58: 227-229.
50. Buttery LD, Springall DR, Chester AH, Evans TJ, Standfield EN, et al. (1996) Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 75: 77-85.
51. Agusti A, Morla M, Sauleda J, Saus C, Busquets X, (2004) NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 59: 483-487.
52. Hashizume M, Mihara M, (2012) Atherogenic effects of TNF-alpha and IL-6 via up-regulation of scavenger receptors. Cytokine 58: 424-430.
53. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL, (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924.
54. White SJ, Sala-Newby GB, Newby AC, (2011) Overexpression of scavenger receptor LOX-1 in endothelial cells promotes atherogenesis in the ApoE(-/-) mouse model. Cardiovasc Pathol 20: 369-373.
55. Inoue K, Arai Y, Kurihara H, Kita T, Sawamura T, (2005) Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ Res 97: 176-184.